The global market for Obesity-Diabetes Drug was valued at US$ 59341 million in the year 2024 and is projected to reach a revised size of US$ 99018 million by 2031, growing at a CAGR of 7.5% during the forecast period.

Obesity-Diabetes Drug Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Obesity-Diabetes Drug competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Obesity-Diabetes Drugs are a class of therapeutic agents designed for the integrated management of obesity and type 2 diabetes mellitus. These drugs act through multiple pathways—improving insulin sensitivity, regulating energy metabolism, and modulating appetite control—to achieve dual effects on weight reduction and glycemic control. Key mechanisms include GLP-1 receptor agonists, GIP/GLP-1 dual agonists, insulin secretagogues, and novel lipid metabolism modulators. With the growing prevalence of obesity-diabetes comorbidity, the boundary between anti-obesity and antidiabetic medications is increasingly blurred, leading to a trend toward “metabolic-integrated” therapies. Beyond blood glucose and weight control, these drugs also reduce cardiovascular risk, improve hepatic lipid metabolism, and alleviate systemic inflammation, positioning them as one of the most promising directions in global metabolic disease treatment.In 2024, global Obesity-Diabetes Drug production reached approximately 118.68 million units, with an average global market price of around US$ 500 perunit.The average gross profit margin of this product is 75%.

The global co-prevalence of obesity and type 2 diabetes continues to drive rapid market expansion for obesity-diabetes drugs. Aging populations, sedentary lifestyles, and widespread high-calorie diets have caused a surge in metabolic syndrome cases, creating a vast potential patient pool. The new generation of GLP-1 and dual agonist drugs demonstrates superior weight loss and glycemic control outcomes, improving both patient compliance and physician prescription rates. Growing emphasis on chronic disease management across healthcare systems has expanded reimbursement coverage through public and private insurance. Meanwhile, collaboration between major pharmaceutical companies and biotech firms is accelerating innovation pipelines and clinical adoption, fueling sustainable market growth.Despite strong growth potential, the obesity-diabetes drug market faces significant challenges. Drug development is costly and lengthy, with stringent regulatory requirements for long-term efficacy and safety. Some GLP-1 class drugs cause gastrointestinal side effects, reducing long-term adherence. High prices and limited insurance reimbursement restrict accessibility in low- and middle-income countries. Competition is intensifying as major players like Novo Nordisk and Eli Lilly have established strong brand and technology barriers, creating high entry thresholds for newcomers. Furthermore, limited patient awareness and the need for long-term clinical outcome validation add uncertainty to the market outlook.

Downstream demand is shifting toward diversification and integration. Hospitals and metabolic clinics are transitioning from glucose-centric therapy to comprehensive weight and metabolic management, driving rapid adoption of GLP-1 and GIP/GLP-1 dual agonists. Rising attention to early-stage metabolic disorders and mild obesity among consumers is fostering a preventive and lifestyle-integrated approach. The integration of digital health platforms and remote monitoring tools enables personalized medication management. Pharmaceutical companies are also collaborating with nutrition, fitness, and wearable technology firms to expand their product ecosystems and meet holistic healthcare needs spanning from clinical treatment to preventive wellness.

The upstream supply chain of obesity-diabetes drugs mainly consists of peptide synthesis materials, formulation excipients, and components for injectable delivery systems. GLP-1 drugs rely on peptide-based active ingredients requiring high-purity amino acids and advanced solid-phase synthesis technologies, with strict aseptic and purification standards. Delivery carriers such as liposomes, sustained-release microspheres, and PEGylation materials determine the pharmacokinetic profile and stability of the final drug. Injection pens and prefilled syringes play key roles in patient experience and product acceptance. However, fluctuations in raw material prices, patent monopolies, and limited availability of specialized manufacturing equipment pose potential bottlenecks in the upstream supply chain.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Obesity-Diabetes Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Obesity-Diabetes Drug.

The Obesity-Diabetes Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Obesity-Diabetes Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, by Patient Type and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Obesity-Diabetes Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, by Patient Type and by regions.

Scope of Obesity-Diabetes Drug Market Report

Report Metric	Details
Report Name	Obesity-Diabetes Drug Market
Accounted market size in year	US$ 59341 million
Forecasted market size in 2031	US$ 99018 million
CAGR	7.5%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	GLP-1 Receptor Agonists Insulin Secretagogues Other
Segment by Patient Type	Obese without Diabete Obese with Type 2 Diabetes Other
Segment by Administration Route	Injectable Formulations Oral Administration Other
Segment by Application	Hospital Clinic Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Sanofi, Vertex Pharmaceuticals, AstraZeneca, MannKind Corporation, BENEMAE, Xeris Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Obesity-Diabetes Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Obesity-Diabetes Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Obesity-Diabetes Drug Market growing?

Ans: The Obesity-Diabetes Drug Market witnessing a CAGR of 7.5% during the forecast period 2025-2031.

What is the Obesity-Diabetes Drug Market size in 2031?

Ans: The Obesity-Diabetes Drug Market size in 2031 will be US$ 99018 million.

Who are the main players in the Obesity-Diabetes Drug Market report?

Ans: The main players in the Obesity-Diabetes Drug Market are Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Sanofi, Vertex Pharmaceuticals, AstraZeneca, MannKind Corporation, BENEMAE, Xeris Pharmaceuticals

What are the Application segmentation covered in the Obesity-Diabetes Drug Market report?

Ans: The Applications covered in the Obesity-Diabetes Drug Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Obesity-Diabetes Drug Market report?

Ans: The Types covered in the Obesity-Diabetes Drug Market report are Obese without Diabete, Obese with Type 2 Diabetes, Other

1 Obesity-Diabetes Drug Market Overview

1.1 Product Definition

1.2 Obesity-Diabetes Drug by Type

1.2.1 Global Obesity-Diabetes Drug Market Value Comparison by Type (2024 VS 2031)

1.2.2 GLP-1 Receptor Agonists

1.2.3 Insulin Secretagogues

1.2.4 Other

1.3 Obesity-Diabetes Drug by Patient Type

1.3.1 Global Obesity-Diabetes Drug Market Value Comparison by Patient Type: 2024 VS 2031

1.3.2 Obese without Diabete

1.3.3 Obese with Type 2 Diabetes

1.3.4 Other

1.4 Obesity-Diabetes Drug by Administration Route

1.4.1 Global Obesity-Diabetes Drug Market Value Comparison by Administration Route: 2024 VS 2031

1.4.2 Injectable Formulations

1.4.3 Oral Administration

1.4.4 Other

1.5 Obesity-Diabetes Drug by Application

1.5.1 Global Obesity-Diabetes Drug Market Value by Application (2024 VS 2031)

1.5.2 Hospital

1.5.3 Clinic

1.5.4 Other

1.6 Global Obesity-Diabetes Drug Market Size Estimates and Forecasts

1.6.1 Global Obesity-Diabetes Drug Revenue 2020-2031

1.6.2 Global Obesity-Diabetes Drug Sales 2020-2031

1.6.3 Global Obesity-Diabetes Drug Market Average Price (2020-2031)

1.7 Assumptions and Limitations

2 Obesity-Diabetes Drug Market Competition by Manufacturers

2.1 Global Obesity-Diabetes Drug Sales Market Share by Manufacturers (2020-2025)

2.2 Global Obesity-Diabetes Drug Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Obesity-Diabetes Drug Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Obesity-Diabetes Drug, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Obesity-Diabetes Drug, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Obesity-Diabetes Drug, Product Type & Application

2.7 Global Key Manufacturers of Obesity-Diabetes Drug, Date of Enter into This Industry

2.8 Global Obesity-Diabetes Drug Market Competitive Situation and Trends

2.8.1 Global Obesity-Diabetes Drug Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Obesity-Diabetes Drug Players Market Share by Revenue

2.8.3 Global Obesity-Diabetes Drug Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Obesity-Diabetes Drug Market Scenario by Region

3.1 Global Obesity-Diabetes Drug Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Obesity-Diabetes Drug Sales by Region: 2020-2031

3.2.1 Global Obesity-Diabetes Drug Sales by Region: 2020-2025

3.2.2 Global Obesity-Diabetes Drug Sales by Region: 2026-2031

3.3 Global Obesity-Diabetes Drug Revenue by Region: 2020-2031

3.3.1 Global Obesity-Diabetes Drug Revenue by Region: 2020-2025

3.3.2 Global Obesity-Diabetes Drug Revenue by Region: 2026-2031

3.4 North America Obesity-Diabetes Drug Market Facts & Figures by Country

3.4.1 North America Obesity-Diabetes Drug Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Obesity-Diabetes Drug Sales by Country (2020-2031)

3.4.3 North America Obesity-Diabetes Drug Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Obesity-Diabetes Drug Market Facts & Figures by Country

3.5.1 Europe Obesity-Diabetes Drug Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Obesity-Diabetes Drug Sales by Country (2020-2031)

3.5.3 Europe Obesity-Diabetes Drug Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Obesity-Diabetes Drug Market Facts & Figures by Region

3.6.1 Asia Pacific Obesity-Diabetes Drug Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Obesity-Diabetes Drug Sales by Region (2020-2031)

3.6.3 Asia Pacific Obesity-Diabetes Drug Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Obesity-Diabetes Drug Market Facts & Figures by Country

3.7.1 Latin America Obesity-Diabetes Drug Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Obesity-Diabetes Drug Sales by Country (2020-2031)

3.7.3 Latin America Obesity-Diabetes Drug Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Obesity-Diabetes Drug Market Facts & Figures by Country

3.8.1 Middle East and Africa Obesity-Diabetes Drug Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Obesity-Diabetes Drug Sales by Country (2020-2031)

3.8.3 Middle East and Africa Obesity-Diabetes Drug Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Obesity-Diabetes Drug Sales by Type (2020-2031)

4.1.1 Global Obesity-Diabetes Drug Sales by Type (2020-2025)

4.1.2 Global Obesity-Diabetes Drug Sales by Type (2026-2031)

4.1.3 Global Obesity-Diabetes Drug Sales Market Share by Type (2020-2031)

4.2 Global Obesity-Diabetes Drug Revenue by Type (2020-2031)

4.2.1 Global Obesity-Diabetes Drug Revenue by Type (2020-2025)

4.2.2 Global Obesity-Diabetes Drug Revenue by Type (2026-2031)

4.2.3 Global Obesity-Diabetes Drug Revenue Market Share by Type (2020-2031)

4.3 Global Obesity-Diabetes Drug Price by Type (2020-2031)

5 Segment by Application

5.1 Global Obesity-Diabetes Drug Sales by Application (2020-2031)

5.1.1 Global Obesity-Diabetes Drug Sales by Application (2020-2025)

5.1.2 Global Obesity-Diabetes Drug Sales by Application (2026-2031)

5.1.3 Global Obesity-Diabetes Drug Sales Market Share by Application (2020-2031)

5.2 Global Obesity-Diabetes Drug Revenue by Application (2020-2031)

5.2.1 Global Obesity-Diabetes Drug Revenue by Application (2020-2025)

5.2.2 Global Obesity-Diabetes Drug Revenue by Application (2026-2031)

5.2.3 Global Obesity-Diabetes Drug Revenue Market Share by Application (2020-2031)

5.3 Global Obesity-Diabetes Drug Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Novo Nordisk

6.1.1 Novo Nordisk Company Information

6.1.2 Novo Nordisk Description and Business Overview

6.1.3 Novo Nordisk Obesity-Diabetes Drug Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Novo Nordisk Obesity-Diabetes Drug Product Portfolio

6.1.5 Novo Nordisk Recent Developments/Updates

6.2 Eli Lilly

6.2.1 Eli Lilly Company Information

6.2.2 Eli Lilly Description and Business Overview

6.2.3 Eli Lilly Obesity-Diabetes Drug Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Eli Lilly Obesity-Diabetes Drug Product Portfolio

6.2.5 Eli Lilly Recent Developments/Updates

6.3 Boehringer Ingelheim

6.3.1 Boehringer Ingelheim Company Information

6.3.2 Boehringer Ingelheim Description and Business Overview

6.3.3 Boehringer Ingelheim Obesity-Diabetes Drug Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Boehringer Ingelheim Obesity-Diabetes Drug Product Portfolio

6.3.5 Boehringer Ingelheim Recent Developments/Updates

6.4 Sanofi

6.4.1 Sanofi Company Information

6.4.2 Sanofi Description and Business Overview

6.4.3 Sanofi Obesity-Diabetes Drug Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Sanofi Obesity-Diabetes Drug Product Portfolio

6.4.5 Sanofi Recent Developments/Updates

6.5 Vertex Pharmaceuticals

6.5.1 Vertex Pharmaceuticals Company Information

6.5.2 Vertex Pharmaceuticals Description and Business Overview

6.5.3 Vertex Pharmaceuticals Obesity-Diabetes Drug Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Vertex Pharmaceuticals Obesity-Diabetes Drug Product Portfolio

6.5.5 Vertex Pharmaceuticals Recent Developments/Updates

6.6 AstraZeneca

6.6.1 AstraZeneca Company Information

6.6.2 AstraZeneca Description and Business Overview

6.6.3 AstraZeneca Obesity-Diabetes Drug Sales, Revenue and Gross Margin (2020-2025)

6.6.4 AstraZeneca Obesity-Diabetes Drug Product Portfolio

6.6.5 AstraZeneca Recent Developments/Updates

6.7 MannKind Corporation

6.7.1 MannKind Corporation Company Information

6.7.2 MannKind Corporation Description and Business Overview

6.7.3 MannKind Corporation Obesity-Diabetes Drug Sales, Revenue and Gross Margin (2020-2025)

6.7.4 MannKind Corporation Obesity-Diabetes Drug Product Portfolio

6.7.5 MannKind Corporation Recent Developments/Updates

6.8 BENEMAE

6.8.1 BENEMAE Company Information

6.8.2 BENEMAE Description and Business Overview

6.8.3 BENEMAE Obesity-Diabetes Drug Sales, Revenue and Gross Margin (2020-2025)

6.8.4 BENEMAE Obesity-Diabetes Drug Product Portfolio

6.8.5 BENEMAE Recent Developments/Updates

6.9 Xeris Pharmaceuticals

6.9.1 Xeris Pharmaceuticals Company Information

6.9.2 Xeris Pharmaceuticals Description and Business Overview

6.9.3 Xeris Pharmaceuticals Obesity-Diabetes Drug Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Xeris Pharmaceuticals Obesity-Diabetes Drug Product Portfolio

6.9.5 Xeris Pharmaceuticals Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Obesity-Diabetes Drug Industry Chain Analysis

7.2 Obesity-Diabetes Drug Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Obesity-Diabetes Drug Production Mode & Process Analysis

7.4 Obesity-Diabetes Drug Sales and Marketing

7.4.1 Obesity-Diabetes Drug Sales Channels

7.4.2 Obesity-Diabetes Drug Distributors

7.5 Obesity-Diabetes Drug Customer Analysis

8 Obesity-Diabetes Drug Market Dynamics

8.1 Obesity-Diabetes Drug Industry Trends

8.2 Obesity-Diabetes Drug Market Drivers

8.3 Obesity-Diabetes Drug Market Challenges

8.4 Obesity-Diabetes Drug Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Vertex Pharmaceuticals

Astrazeneca plc

MannKind Corporation

Benemae

Xeris Pharmaceuticals

List of Tables

Table 1. Global Obesity-Diabetes Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Obesity-Diabetes Drug Market Value by Patient Type, (US$ Million) & (2024 VS 2031)

Table 3. Global Obesity-Diabetes Drug Market Value by Administration Route, (US$ Million) & (2024 VS 2031)

Table 4. Global Obesity-Diabetes Drug Market Value by Application (2024 VS 2031) & (US$ Million)

Table 5. Global Obesity-Diabetes Drug Market Competitive Situation by Manufacturers in 2024

Table 6. Global Obesity-Diabetes Drug Sales (K Units) of Key Manufacturers (2020-2025)

Table 7. Global Obesity-Diabetes Drug Sales Market Share by Manufacturers (2020-2025)

Table 8. Global Obesity-Diabetes Drug Revenue (US$ Million) by Manufacturers (2020-2025)

Table 9. Global Obesity-Diabetes Drug Revenue Share by Manufacturers (2020-2025)

Table 10. Global Market Obesity-Diabetes Drug Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 11. Global Key Players of Obesity-Diabetes Drug, Industry Ranking, 2022 VS 2023 VS 2024

Table 12. Global Key Manufacturers of Obesity-Diabetes Drug, Manufacturing Sites & Headquarters

Table 13. Global Key Manufacturers of Obesity-Diabetes Drug, Product Type & Application

Table 14. Global Key Manufacturers of Obesity-Diabetes Drug, Date of Enter into This Industry

Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 16. Global Obesity-Diabetes Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Obesity-Diabetes Drug as of 2024)

Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 18. Global Obesity-Diabetes Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 19. Global Obesity-Diabetes Drug Sales by Region (2020-2025) & (K Units)

Table 20. Global Obesity-Diabetes Drug Sales Market Share by Region (2020-2025)

Table 21. Global Obesity-Diabetes Drug Sales by Region (2026-2031) & (K Units)

Table 22. Global Obesity-Diabetes Drug Sales Market Share by Region (2026-2031)

Table 23. Global Obesity-Diabetes Drug Revenue by Region (2020-2025) & (US$ Million)

Table 24. Global Obesity-Diabetes Drug Revenue Market Share by Region (2020-2025)

Table 25. Global Obesity-Diabetes Drug Revenue by Region (2026-2031) & (US$ Million)

Table 26. Global Obesity-Diabetes Drug Revenue Market Share by Region (2026-2031)

Table 27. North America Obesity-Diabetes Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 28. North America Obesity-Diabetes Drug Sales by Country (2020-2025) & (K Units)

Table 29. North America Obesity-Diabetes Drug Sales by Country (2026-2031) & (K Units)

Table 30. North America Obesity-Diabetes Drug Revenue by Country (2020-2025) & (US$ Million)

Table 31. North America Obesity-Diabetes Drug Revenue by Country (2026-2031) & (US$ Million)

Table 32. Europe Obesity-Diabetes Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 33. Europe Obesity-Diabetes Drug Sales by Country (2020-2025) & (K Units)

Table 34. Europe Obesity-Diabetes Drug Sales by Country (2026-2031) & (K Units)

Table 35. Europe Obesity-Diabetes Drug Revenue by Country (2020-2025) & (US$ Million)

Table 36. Europe Obesity-Diabetes Drug Revenue by Country (2026-2031) & (US$ Million)

Table 37. Asia Pacific Obesity-Diabetes Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 38. Asia Pacific Obesity-Diabetes Drug Sales by Region (2020-2025) & (K Units)

Table 39. Asia Pacific Obesity-Diabetes Drug Sales by Region (2026-2031) & (K Units)

Table 40. Asia Pacific Obesity-Diabetes Drug Revenue by Region (2020-2025) & (US$ Million)

Table 41. Asia Pacific Obesity-Diabetes Drug Revenue by Region (2026-2031) & (US$ Million)

Table 42. Latin America Obesity-Diabetes Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 43. Latin America Obesity-Diabetes Drug Sales by Country (2020-2025) & (K Units)

Table 44. Latin America Obesity-Diabetes Drug Sales by Country (2026-2031) & (K Units)

Table 45. Latin America Obesity-Diabetes Drug Revenue by Country (2020-2025) & (US$ Million)

Table 46. Latin America Obesity-Diabetes Drug Revenue by Country (2026-2031) & (US$ Million)

Table 47. Middle East and Africa Obesity-Diabetes Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 48. Middle East and Africa Obesity-Diabetes Drug Sales by Country (2020-2025) & (K Units)

Table 49. Middle East and Africa Obesity-Diabetes Drug Sales by Country (2026-2031) & (K Units)

Table 50. Middle East and Africa Obesity-Diabetes Drug Revenue by Country (2020-2025) & (US$ Million)

Table 51. Middle East and Africa Obesity-Diabetes Drug Revenue by Country (2026-2031) & (US$ Million)

Table 52. Global Obesity-Diabetes Drug Sales (K Units) by Type (2020-2025)

Table 53. Global Obesity-Diabetes Drug Sales (K Units) by Type (2026-2031)

Table 54. Global Obesity-Diabetes Drug Sales Market Share by Type (2020-2025)

Table 55. Global Obesity-Diabetes Drug Sales Market Share by Type (2026-2031)

Table 56. Global Obesity-Diabetes Drug Revenue (US$ Million) by Type (2020-2025)

Table 57. Global Obesity-Diabetes Drug Revenue (US$ Million) by Type (2026-2031)

Table 58. Global Obesity-Diabetes Drug Revenue Market Share by Type (2020-2025)

Table 59. Global Obesity-Diabetes Drug Revenue Market Share by Type (2026-2031)

Table 60. Global Obesity-Diabetes Drug Price (US$/Unit) by Type (2020-2025)

Table 61. Global Obesity-Diabetes Drug Price (US$/Unit) by Type (2026-2031)

Table 62. Global Obesity-Diabetes Drug Sales (K Units) by Application (2020-2025)

Table 63. Global Obesity-Diabetes Drug Sales (K Units) by Application (2026-2031)

Table 64. Global Obesity-Diabetes Drug Sales Market Share by Application (2020-2025)

Table 65. Global Obesity-Diabetes Drug Sales Market Share by Application (2026-2031)

Table 66. Global Obesity-Diabetes Drug Revenue (US$ Million) by Application (2020-2025)

Table 67. Global Obesity-Diabetes Drug Revenue (US$ Million) by Application (2026-2031)

Table 68. Global Obesity-Diabetes Drug Revenue Market Share by Application (2020-2025)

Table 69. Global Obesity-Diabetes Drug Revenue Market Share by Application (2026-2031)

Table 70. Global Obesity-Diabetes Drug Price (US$/Unit) by Application (2020-2025)

Table 71. Global Obesity-Diabetes Drug Price (US$/Unit) by Application (2026-2031)

Table 72. Novo Nordisk Company Information

Table 73. Novo Nordisk Description and Business Overview

Table 74. Novo Nordisk Obesity-Diabetes Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 75. Novo Nordisk Obesity-Diabetes Drug Product

Table 76. Novo Nordisk Recent Developments/Updates

Table 77. Eli Lilly Company Information

Table 78. Eli Lilly Description and Business Overview

Table 79. Eli Lilly Obesity-Diabetes Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 80. Eli Lilly Obesity-Diabetes Drug Product

Table 81. Eli Lilly Recent Developments/Updates

Table 82. Boehringer Ingelheim Company Information

Table 83. Boehringer Ingelheim Description and Business Overview

Table 84. Boehringer Ingelheim Obesity-Diabetes Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 85. Boehringer Ingelheim Obesity-Diabetes Drug Product

Table 86. Boehringer Ingelheim Recent Developments/Updates

Table 87. Sanofi Company Information

Table 88. Sanofi Description and Business Overview

Table 89. Sanofi Obesity-Diabetes Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 90. Sanofi Obesity-Diabetes Drug Product

Table 91. Sanofi Recent Developments/Updates

Table 92. Vertex Pharmaceuticals Company Information

Table 93. Vertex Pharmaceuticals Description and Business Overview

Table 94. Vertex Pharmaceuticals Obesity-Diabetes Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 95. Vertex Pharmaceuticals Obesity-Diabetes Drug Product

Table 96. Vertex Pharmaceuticals Recent Developments/Updates

Table 97. AstraZeneca Company Information

Table 98. AstraZeneca Description and Business Overview

Table 99. AstraZeneca Obesity-Diabetes Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 100. AstraZeneca Obesity-Diabetes Drug Product

Table 101. AstraZeneca Recent Developments/Updates

Table 102. MannKind Corporation Company Information

Table 103. MannKind Corporation Description and Business Overview

Table 104. MannKind Corporation Obesity-Diabetes Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 105. MannKind Corporation Obesity-Diabetes Drug Product

Table 106. MannKind Corporation Recent Developments/Updates

Table 107. BENEMAE Company Information

Table 108. BENEMAE Description and Business Overview

Table 109. BENEMAE Obesity-Diabetes Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 110. BENEMAE Obesity-Diabetes Drug Product

Table 111. BENEMAE Recent Developments/Updates

Table 112. Xeris Pharmaceuticals Company Information

Table 113. Xeris Pharmaceuticals Description and Business Overview

Table 114. Xeris Pharmaceuticals Obesity-Diabetes Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 115. Xeris Pharmaceuticals Obesity-Diabetes Drug Product

Table 116. Xeris Pharmaceuticals Recent Developments/Updates

Table 117. Key Raw Materials Lists

Table 118. Raw Materials Key Suppliers Lists

Table 119. Obesity-Diabetes Drug Distributors List

Table 120. Obesity-Diabetes Drug Customers List

Table 121. Obesity-Diabetes Drug Market Trends

Table 122. Obesity-Diabetes Drug Market Drivers

Table 123. Obesity-Diabetes Drug Market Challenges

Table 124. Obesity-Diabetes Drug Market Restraints

Table 125. Research Programs/Design for This Report

Table 126. Key Data Information from Secondary Sources

Table 127. Key Data Information from Primary Sources

Table 128. Authors List of This Report

List of Figures

Figure 1. Product Picture of Obesity-Diabetes Drug

Figure 2. Global Obesity-Diabetes Drug Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Obesity-Diabetes Drug Market Share by Type: 2024 & 2031

Figure 4. GLP-1 Receptor Agonists Product Picture

Figure 5. Insulin Secretagogues Product Picture

Figure 6. Other Product Picture

Figure 7. Global Obesity-Diabetes Drug Market Value by Patient Type, (US$ Million) & (2020-2031)

Figure 8. Global Obesity-Diabetes Drug Market Share by Patient Type: 2024 VS 2031

Figure 9. Obese without Diabete Product Picture

Figure 10. Obese with Type 2 Diabetes Product Picture

Figure 11. Other Product Picture

Figure 12. Global Obesity-Diabetes Drug Market Value by Administration Route, (US$ Million) & (2020-2031)

Figure 13. Global Obesity-Diabetes Drug Market Share by Administration Route: 2024 VS 2031

Figure 14. Injectable Formulations Product Picture

Figure 15. Oral Administration Product Picture

Figure 16. Other Product Picture

Figure 17. Global Obesity-Diabetes Drug Market Value by Application (2020-2031) & (US$ Million)

Figure 18. Global Obesity-Diabetes Drug Market Share by Application: 2024 & 2031

Figure 19. Hospital

Figure 20. Clinic

Figure 21. Other

Figure 22. Global Obesity-Diabetes Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 23. Global Obesity-Diabetes Drug Market Size (2020-2031) & (US$ Million)

Figure 24. Global Obesity-Diabetes Drug Sales (2020-2031) & (K Units)

Figure 25. Global Obesity-Diabetes Drug Average Price (US$/Unit) & (2020-2031)

Figure 26. Obesity-Diabetes Drug Report Years Considered

Figure 27. Obesity-Diabetes Drug Sales Share by Manufacturers in 2024

Figure 28. Global Obesity-Diabetes Drug Revenue Share by Manufacturers in 2024

Figure 29. Global 5 and 10 Largest Obesity-Diabetes Drug Players: Market Share by Revenue in Obesity-Diabetes Drug in 2024

Figure 30. Obesity-Diabetes Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 31. Global Obesity-Diabetes Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 32. North America Obesity-Diabetes Drug Sales Market Share by Country (2020-2031)

Figure 33. North America Obesity-Diabetes Drug Revenue Market Share by Country (2020-2031)

Figure 34. United States Obesity-Diabetes Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Canada Obesity-Diabetes Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Europe Obesity-Diabetes Drug Sales Market Share by Country (2020-2031)

Figure 37. Europe Obesity-Diabetes Drug Revenue Market Share by Country (2020-2031)

Figure 38. Germany Obesity-Diabetes Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. France Obesity-Diabetes Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. U.K. Obesity-Diabetes Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Italy Obesity-Diabetes Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Russia Obesity-Diabetes Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Asia Pacific Obesity-Diabetes Drug Sales Market Share by Region (2020-2031)

Figure 44. Asia Pacific Obesity-Diabetes Drug Revenue Market Share by Region (2020-2031)

Figure 45. China Obesity-Diabetes Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Japan Obesity-Diabetes Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. South Korea Obesity-Diabetes Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. India Obesity-Diabetes Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Australia Obesity-Diabetes Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. China Taiwan Obesity-Diabetes Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Southeast Asia Obesity-Diabetes Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Latin America Obesity-Diabetes Drug Sales Market Share by Country (2020-2031)

Figure 53. Latin America Obesity-Diabetes Drug Revenue Market Share by Country (2020-2031)

Figure 54. Mexico Obesity-Diabetes Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 55. Brazil Obesity-Diabetes Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 56. Argentina Obesity-Diabetes Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 57. Colombia Obesity-Diabetes Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 58. Middle East and Africa Obesity-Diabetes Drug Sales Market Share by Country (2020-2031)

Figure 59. Middle East and Africa Obesity-Diabetes Drug Revenue Market Share by Country (2020-2031)

Figure 60. Turkey Obesity-Diabetes Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 61. Saudi Arabia Obesity-Diabetes Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 62. UAE Obesity-Diabetes Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 63. Global Sales Market Share of Obesity-Diabetes Drug by Type (2020-2031)

Figure 64. Global Revenue Market Share of Obesity-Diabetes Drug by Type (2020-2031)

Figure 65. Global Obesity-Diabetes Drug Price (US$/Unit) by Type (2020-2031)

Figure 66. Global Sales Market Share of Obesity-Diabetes Drug by Application (2020-2031)

Figure 67. Global Revenue Market Share of Obesity-Diabetes Drug by Application (2020-2031)

Figure 68. Global Obesity-Diabetes Drug Price (US$/Unit) by Application (2020-2031)

Figure 69. Obesity-Diabetes Drug Value Chain

Figure 70. Channels of Distribution (Direct Vs Distribution)

Figure 71. Bottom-up and Top-down Approaches for This Report

Figure 72. Data Triangulation

Figure 73. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions